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Patients in the conventional diagnosis and staging arm of the trial were recommended to undergo CT guided biopsy or bronchoscopy depending upon whether the primary lesion was peripheral or central. Conventional transbronchial needle aspiration was utilised at the operator's discretion. If the patient was a candidate for radical treatment, a PET-CT scan was recommended. Mediastinoscopy was advised if the presence of FDG avid lymph nodes precluded a radical treatment option. Invasive mediastinal sampling was also recommended in the trial protocol if any mediastinal lymph node was > 1cm in short axis and its result would alter management. However, the protocol did not mandate any specific investigations (other than the exclusion of EBUS-TBNA) and all investigations and their order, including the need for PET-CT scan and mediastinoscopy, were determined by the multi-disciplinary team. Patients in the EBUS arm of the trial were scheduled to undergo EBUS-TBNA as an initial investigation after staging CT scan. Standard videobronchoscopy was permitted as an additional investigation at the same sitting at the operator's discretion. Endoscopic ultrasound guided fine needle aspiration (EUS-FNA) was permitted as an alternative to EBUS-TBNA if a target lesion was not amenable to EBUS-TBNA. Three to 5 passes per lymph node were made. Rapid on-site evaluation of samples was not performed. Specimens obtained were smeared onto slides and also spun down for cell block analysis. Any cores obtained were transferred directly into formalin and subsequent histopathological examination. Samples from EBUS-TBNA underwent routine laboratory processing.
Results from EBUS-TBNA were discussed in multi-disciplinary team meetings in the referring hospitals and further investigations were requested as required. Figure S4 : Exploratory analysis of non-small cell lung cancer survival according to treatment modality in the Lung-BOOST trial.
As expected, survival for patients with Stage I and II non-small cell lung cancer undergoing surgery is superior to those patients with more advanced stages not undergoing surgery. However, in patients undergoing surgery there is a trend towards improved survival in patients who have pre-operative EBUS compared to those patients who undergo conventional diagnosis and staging (HR 0.37 (0.10, 1.32), P=0.125). There also may be improved survival in patients undergoing EBUS followed by nonsurgical treatments compared to patients undergoing conventional techniques followed by nonsurgical treatments (HR 0.68 (0.41, 1.13), P=0.137). These potential differences in survival may reflect a more accurate staging resulting in patients receiving more appropriate and therefore effective therapy for their disease stage. Years from first out-patient appointment 
